Matches in SemOpenAlex for { <https://semopenalex.org/work/W2938695787> ?p ?o ?g. }
- W2938695787 endingPage "e192416" @default.
- W2938695787 startingPage "e192416" @default.
- W2938695787 abstract "<h3>Importance</h3> Head-to-head randomized clinical trials showed greater efficacy of denosumab vs alendronate in improving bone mineral density. Although there is an association of changes in bone mineral density with reductions in fracture risk, the magnitude of the association is not well established. <h3>Objective</h3> To compare the risk of hip and any fracture in patients treated with denosumab and alendronate in routine practice settings. <h3>Design, Setting, and Participants</h3> This Danish nationwide, population-based, historical cohort study of a population with universal access to health care used prospectively collected, individually linked data from Danish health registries with complete follow-up. Cohorts consisted of 92 355 individuals 50 years or older who were new users of denosumab (n = 4624) or alendronate (n = 87 731) from May 2010 to December 2017 after at least 1 year without an antiosteoporosis medication dispensing. <h3>Exposures</h3> Initiation of denosumab or alendronate. <h3>Main Outcomes and Measures</h3> The primary outcome was hospitalization for hip fracture, and the secondary outcome was hospitalization for any fracture. Inverse probability of treatment weights and the intention-to-treat approach were used to calculate cumulative incidences and adjusted hazard ratios (aHRs) with 95% CIs. <h3>Results</h3> Of the 92 355 included patients, 75 046 (81.3%) were women, and the mean (SD) age was 71 (10) years. The denosumab cohort had a lower proportion of men than the alendronate cohort (12.7% [589] vs 19.0% [16 700]), while age distributions were similar in the 2 cohorts. Within 3 years of follow-up, initiation of denosumab or alendronate was associated with cumulative incidences of 3.7% and 3.1%, respectively, for hip fracture and 9.0% and 9.0%, respectively, for any fracture. Overall, the aHRs for denosumab vs alendronate were 1.08 (95% CI, 0.92-1.28) for hip fracture and 0.92 (95% CI, 0.83-1.02) for any fracture. The aHR of denosumab vs alendronate for hip fracture was 1.07 (95% CI, 0.85-1.34) among patients with a history of any fracture and 1.05 (95% CI, 0.83-1.32) among patients without history of fracture. The aHR for any fracture for denosumab vs alendronate was 0.84 (95% CI, 0.71-0.98) among patients with a history of any fracture and 0.77 (95% CI, 0.64-0.93) among patients with no history of fracture. <h3>Conclusions and Relevance</h3> Treatment with denosumab and alendronate was associated with similar risks of hip or any fracture over a 3-year period, regardless of fracture history." @default.
- W2938695787 created "2019-04-25" @default.
- W2938695787 creator A5032326570 @default.
- W2938695787 creator A5033040903 @default.
- W2938695787 creator A5038076932 @default.
- W2938695787 creator A5077930672 @default.
- W2938695787 creator A5084136574 @default.
- W2938695787 date "2019-04-19" @default.
- W2938695787 modified "2023-10-16" @default.
- W2938695787 title "Comparison of Risk of Osteoporotic Fracture in Denosumab vs Alendronate Treatment Within 3 Years of Initiation" @default.
- W2938695787 cites W1849521086 @default.
- W2938695787 cites W1906465678 @default.
- W2938695787 cites W1978670003 @default.
- W2938695787 cites W1982942836 @default.
- W2938695787 cites W1989860636 @default.
- W2938695787 cites W1994955754 @default.
- W2938695787 cites W1997823019 @default.
- W2938695787 cites W2006585716 @default.
- W2938695787 cites W2011966376 @default.
- W2938695787 cites W2021456465 @default.
- W2938695787 cites W2021748249 @default.
- W2938695787 cites W2028200045 @default.
- W2938695787 cites W2036125852 @default.
- W2938695787 cites W2039986085 @default.
- W2938695787 cites W2040645421 @default.
- W2938695787 cites W2047041395 @default.
- W2938695787 cites W2048964656 @default.
- W2938695787 cites W2052957337 @default.
- W2938695787 cites W2053237747 @default.
- W2938695787 cites W2073101005 @default.
- W2938695787 cites W2080276371 @default.
- W2938695787 cites W2107177524 @default.
- W2938695787 cites W2107490395 @default.
- W2938695787 cites W2110818436 @default.
- W2938695787 cites W2118914286 @default.
- W2938695787 cites W2135203315 @default.
- W2938695787 cites W2157410452 @default.
- W2938695787 cites W2160005424 @default.
- W2938695787 cites W2219591537 @default.
- W2938695787 cites W2344978333 @default.
- W2938695787 cites W2346267426 @default.
- W2938695787 cites W2482202957 @default.
- W2938695787 cites W2589046969 @default.
- W2938695787 cites W2604288947 @default.
- W2938695787 cites W4230131604 @default.
- W2938695787 cites W4231253172 @default.
- W2938695787 cites W4233124781 @default.
- W2938695787 cites W4234543098 @default.
- W2938695787 cites W4240851819 @default.
- W2938695787 cites W4253923463 @default.
- W2938695787 cites W4254637496 @default.
- W2938695787 cites W4296974701 @default.
- W2938695787 doi "https://doi.org/10.1001/jamanetworkopen.2019.2416" @default.
- W2938695787 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6481596" @default.
- W2938695787 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31002319" @default.
- W2938695787 hasPublicationYear "2019" @default.
- W2938695787 type Work @default.
- W2938695787 sameAs 2938695787 @default.
- W2938695787 citedByCount "19" @default.
- W2938695787 countsByYear W29386957872019 @default.
- W2938695787 countsByYear W29386957872020 @default.
- W2938695787 countsByYear W29386957872021 @default.
- W2938695787 countsByYear W29386957872022 @default.
- W2938695787 countsByYear W29386957872023 @default.
- W2938695787 crossrefType "journal-article" @default.
- W2938695787 hasAuthorship W2938695787A5032326570 @default.
- W2938695787 hasAuthorship W2938695787A5033040903 @default.
- W2938695787 hasAuthorship W2938695787A5038076932 @default.
- W2938695787 hasAuthorship W2938695787A5077930672 @default.
- W2938695787 hasAuthorship W2938695787A5084136574 @default.
- W2938695787 hasBestOaLocation W29386957871 @default.
- W2938695787 hasConcept C126322002 @default.
- W2938695787 hasConcept C201903717 @default.
- W2938695787 hasConcept C207103383 @default.
- W2938695787 hasConcept C2776286101 @default.
- W2938695787 hasConcept C2776541429 @default.
- W2938695787 hasConcept C2776886416 @default.
- W2938695787 hasConcept C2908647359 @default.
- W2938695787 hasConcept C44249647 @default.
- W2938695787 hasConcept C50382708 @default.
- W2938695787 hasConcept C71924100 @default.
- W2938695787 hasConcept C72563966 @default.
- W2938695787 hasConcept C99454951 @default.
- W2938695787 hasConceptScore W2938695787C126322002 @default.
- W2938695787 hasConceptScore W2938695787C201903717 @default.
- W2938695787 hasConceptScore W2938695787C207103383 @default.
- W2938695787 hasConceptScore W2938695787C2776286101 @default.
- W2938695787 hasConceptScore W2938695787C2776541429 @default.
- W2938695787 hasConceptScore W2938695787C2776886416 @default.
- W2938695787 hasConceptScore W2938695787C2908647359 @default.
- W2938695787 hasConceptScore W2938695787C44249647 @default.
- W2938695787 hasConceptScore W2938695787C50382708 @default.
- W2938695787 hasConceptScore W2938695787C71924100 @default.
- W2938695787 hasConceptScore W2938695787C72563966 @default.
- W2938695787 hasConceptScore W2938695787C99454951 @default.
- W2938695787 hasIssue "4" @default.
- W2938695787 hasLocation W29386957871 @default.
- W2938695787 hasLocation W29386957872 @default.